BioMed Research International

BioMed Research International / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 156356 | 9 pages |

Durable Expression of Minicircle DNA-Liposome-Delivered Androgen Receptor cDNA in Mice with Hepatocellular Carcinoma

Academic Editor: Guillermo Mazzolini
Received04 Sep 2013
Revised25 Dec 2013
Accepted21 Jan 2014
Published06 Mar 2014


Background. The most common gene-based cancer therapies involve the suppression of oncogenic molecules and enhancement of the expression of tumor-suppressor genes. Studies in noncancer disease animal models have shown that minicircle (MC) DNA vectors are easy to deliver and that the proteins from said MC-carrying DNA vectors are expressed over a long period of time. However, delivery of therapeutic genes via a liposome-mediated, MC DNA complex has never been tested in vascular-rich hepatocellular carcinoma (HCC). Liposome-mediated DNA delivery exhibits high in vivo transfection efficiency and minimal systemic immune response, thereby allowing for repetitive interventions. In this study, we evaluated the efficacy of delivering an MC-liposome vector containing a 3.2 kb androgen receptor (AR; HCC metastasis suppressor) cDNA into Hepatitis B Virus- (HBV-) induced HCC mouse livers. Results. Protein expression and promoter luciferase assays revealed that liposome-encapsulated MC-AR resulted in abundant functional expression of AR protein (100 kD) for up to two weeks. The AR cDNA was also successfully delivered into normal livers and diseased livers, where it was persistently expressed. In both normal livers and livers with tumors, the expression of AR was detectable for up to 60 days. Conclusion. Our results show that an MC/liposome delivery system might improve the efficacy of gene therapy in patients with HCC.

1. Introduction

Most solid tumors possess characteristics that are not observed in normal tissues, such as extensive angiogenesis and hence hyper-vasculature, defective vascular architecture, impaired lymphatic drainage/recovery systems, and greatly increased production of a number of permeability mediators [1]. The enhanced permeability and retention (EPR) effect is a phenomenon unique to and ubiquitous in tumors which allows macromolecules such as lipids to enter the tumor interstitial space (enhanced permeability) where they are sequestered due to suppressed lymphatic filtration (retention). The EPR effect provides a great opportunity for more selective targeting of lipid- or polymer-conjugated anticancer drugs, such as SMANCS [2], PK-1 [3], and liposome-encapsulated DNA to the tumor.

The rapid injection of a large volume of DNA solution into a vein was shown by Liu et al. to be an effective method for transfecting DNA into liver, lung, kidney, and heart [4]. The procedure, known as the hydrodynamic method, involves the application of controlled hydrodynamic pressure in capillaries to enhance endothelial and parenchymal cell permeability as a driving force for in vivo gene transfer. Gao et al. reported that the injection of a large volume of DNA solution (8~12% of body weight) within a short time (3~5 s) can generate a transfection efficiency of up to 40% in hepatocytes [5]. This method has been used for delivery of DNA that code for small proteins, such as hemophilia factors [6, 7], cytokines [8], hepatic growth factors [9], and alpha1 antitrypsin [10] in mice and rats. Ortaldo et al. showed that hydrodynamic administration of the IL-2 gene resulted in the rapid and transient production of up to 160 ng/mL of IL-2 protein in serum [11]. However, the problem with the hydrodynamic method for gene transfer in humans is that it is not possible to achieve a good transfection efficiency using a DNA solution of up to 12% of body weight within a short period of time [12].

The duration of protein expression from genes delivered via plasmid DNA delivery is normally transient, lasting for only a few days, followed by a period of prolonged yet low level expression. It is thought that unmethylated CpG sequences in the plasmid backbone stimulate intracellular innate immune responses [13, 14]. Plasmids without CpG sequences (i.e., minicircles (MC)) that no longer contain antibiotic resistance markers or the bacterial origin of replication but contain only the functional part of the plasmid have been shown to prolong the duration of protein expression [15]. These small vectors provide for long-term transient expression of multiple transgenes without the risks of immunogenic responses as in standard plasmids. Chen et al. [15] showed that minicircles expressed 45- and 560-fold more serum human factor IX (FIX) and human alpha1-antitrypsin (AAT) than their parent unrecombined plasmids in mouse livers 3 weeks after transgene delivery. Yew et al. [16] showed that transfection of plasmid DNA depleted of nearly 80% of CpG motifs not only resulted in considerably fewer changes in blood parameters, lower levels of inflammatory cytokines, and less liver damage, but also resulted in longer transgene expression in lung and liver of immunocompetent mice than in mice that had been transfected with unmodified vector.

Hundreds of new cationic lipids have been developed since Felgner et al. first reported that a double-chain monovalent quaternary ammonium lipid, N-[17]-N,N,N- trimethylammonium chloride (DOTAP), effectively binds and delivers DNA to cultured cells [18]. The nonimmunogenic nature and ease of industrial production of these cationic lipids make them appealing for gene transfer. Currently, around 13% of gene therapy trials in progress worldwide employ nonviral liposomal vectors for transgene delivery [19]. The LPD (Liposome-Polycation-DNA) developed by Dr. Gao and Huang has shown a promising nucleic acid carrier for in vivo transfection [20]. LPD was originally designed to evade the clearance by macrophage in the reticuloendothelial system (RES) and efficiently deliver the cargo nucleic acid to the tumor cells [2123]. The LPD was reported to cause very little immunotoxicity and negligible cytokine induction in animal tested [21, 22]. Therefore, LPD has the potential to overcome the transfection limitations of hydrodynamic method. We applied the LPD formula for nucleic acid transfection with minor modification in this present study.

Our team has found that androgen receptor (AR), a 100 kD nuclear transcription factor encoded by the AR gene measuring approximately 3.2 kb [24], promotes HCC initiation [25, 26] and suppresses HCC metastasis [27], indicating that AR plays dual roles in HCC progression. In a previous study, we also provided evidence that combining Sorafenib targeted therapy with ectopic AR expression leads to inhibition of HCC metastasis compared to little AR expression [27]. In this study, we used a human-relevant HBV-HCC mouse model developed by Zheng et al. [28] to examine the efficacy of delivering an MC-liposome vector containing a 3.2 kb androgen receptor (AR; HCC metastasis suppressor) cDNA into Hepatitis B Virus- (HBV-) induced HCC mouse livers and tested whether an MC-carrying AR DNA vector results in expression latency in tumors.

2. Methods

2.1. Construction of AR cDNA into Minicircle Backbone and Mass Production of Minicircle DNA

Parental plasmid with an expression cassette comprising CMV-MCS-EF1α-GFP (SBI) and the kanamycin resistance gene was obtained (System Bioscience, USA). The AR cDNA sequence was released from pBabe.hAR [26] using the restriction enzyme BamH1 and ligated to the parental plasmid using a T4 ligation (NEBL, USA) kit. The resulting plasmid was termed pMCP.hAR and is illustrated in Figure 1(a). In order to produce MC.hAR and MC.GFP DNA, we followed the protocol developed by Kay et al., with slight modifications [29]. In brief, pMCP.hAR and pMCP.GFP were transformed into ZYCY10P3S2T E. coli and the cultures were then incubated at 37°C in 5 mL LB (Luria Broth (Lennox); BIO BASIC, CA) containing 50 μg/mL kanamycin for 2 hrs. We then transferred the E. coli to a 2-liter flask containing 400 mL fresh TB (Terrific Broth; BIO BASIC, CA) and 50 μg/mL kanamycin and then incubated the culture with shaking (250 rpm) at 37°C for 16~18 hrs. We then added an equal volume of LB containing 2% L-arabinose (Sigma-Aldrich), adjusted the pH to 7, and further incubated the solution at 30°C for 5 hours with shaking. A cesium chloride (CsCl) gradient method was used to precipitate the minicircle DNA.

2.2. Preparation of LPD Containing Minicircle DNA

200 μL of LPD for one mouse injection was prepared as previously described [2123]. Briefly, 24 μg minicircle DNA was condensed by 18 μg protamine through electrostatic interaction into nanometric complexes. The complexes were mixed with 30 μL of 100 nm cationic liposome (20 mM) composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP, Avanti Polar Lipids) and cholesterol (Sigma-Aldrich) at 1 : 1 mol ratio. The LPD nanoparticles were then PEGylated by postinsertion of 30 μL of DSPE-PEG (10 mg/mL) at 50°C for 10 minutes.

2.3. Injection of LPD-Containing DNA Complex into HBVtg Mice

A single injection of subminimal dose of hepatic carcinogen diethylnitrosamine (DEN; 2 mg/kg body weight) was given to 12- to 15-day-old HBV-transgenic mice as previously described [28]. The animals were provided by Professor Ou at the University of Southern California [30, 31]. At age 54 weeks, the HBV-lowDEN HCC mice were injected intravenously with 20 μg/100 μL/mouse of LPD (MChAR or MCGFP as control group) twice weekly for 4 consecutive weeks through the caudal vein. The mice were killed two months after minicircle DNA injections. The livers were excised, stored in Tissue-Tek OCT Compound (Sakura; CA90501, USA) for frozen section, and then sliced for GFP signal detection.

2.4. In Vitro Delivery, Long-Term Culture, Immunoblot Assay, and AR Transactivation Luciferase Assay

In order to evaluate the expression latency of minicircle DNA, MC.GFP or MC.hAR was transfected into 293T cells using a calcium phosphate precipitation method [32]. Once cells grew to confluence, 1 in 10 of the cells was subcultured. GFP expression was detected using a fluorescence microscope (Nikon eclipse 80i) at days 2, 6, 10, and 14. The proteins were harvested 2 days after transfection for detection of AR by western blot [27]. The plasmids pRL-TK (transfection control) and ARE-luciferase (ARE-Luc) reporter were applied in this experiment. Briefly, 1-2 × 105 cells were seeded on 24-well plates 24 hrs before transfection. DHT (10−8 M) was added 24 hrs after transfection. Approximately 24 hrs later, cells were harvested and analyzed by the Dual-Luciferase Reporter Assay System (Promega) in combination with a luminometer (Promega).

2.5. Histological Examination of Minicircle-Delivered Gene Expression

Sections of normal and tumor livers were embedded in O.C.T. compound (SAKURA, USA) and frozen at −80°C. The tissue sections (8 μm) were then obtained using a microtome (Leica freezing microtome CM1950, Germany). The sections were then fixed with 1.25% glutaraldehyde for 10 min. All sections were inspected and images were acquired using a Nikon Eclipse 80i camera affixed to a fluorescence microscope (Nikon Microscope Eclipse 80i).

3. Results

3.1. AR Minicircle DNA Construction and Production

In this study, we subcloned a full-length 3.2 kb human AR cDNA into a minicircle parental plasmid (Figure 1(a)). We first linealized pMCP using the BamH1 endonuclease restriction enzyme and then inserted human AR cDNA to generate a 10 kbp pMCP.hAR. To produce minicircle DNA on a larger scale, we performed a two-step incubation of plasmid-transformed ZYCY10P3S2T E. coli. The first incubation was done to replicate competent bacteria on a large scale. We then incubated E. coli in arabinose-containing medium at a low temperature (30°C) to activate phiC31 and ISce1 genes so that the backbone of the plasmid would be degraded. After incubation, the minicircle DNA was extracted using a CsCl gradient method. The construction and verification of minicircle DNA production are shown in Figure 1(b). The parental plasmids and GFP-carrying minicircle DNA were 7 kbp and 3 kbp (Figure 1(b), left panel). The parental plasmid and AR-carrying miniclrcle DNA were 10 kbp and 7 kbp (Figure 1(b), right panel). Our analyses showed that there was little to no contamination.

In order to verify the expression and activity of AR minicircle DNA, we transiently transfected MC.GFP and MC.hAR into 293T cells. The protein expression of AR was examined by immunoblot assay (Figure 2(a)). We found that AR protein was overexpressed in 293T cells. We then examined AR transactivation to verify the proper folding and function of AR (Figure 2(b)). Treatment of MC.hAR transfectants with 10 nM DHT resulted in robust induction of ARE-luciferase activity compared with ARE-luciferase activity in MC.GFP transfectants.

Taken together, we have demonstrated that our protocol results in the successful construction and production of AR minicircle DNA as well as functional expression of AR protein (Figures 1 and 2).

3.2. Durable Expression of Minicircle DNA In Vitro and In Vivo

After establishing our minicircle DNA expression vector, we tested whether AR protein delivered via minicircle DNA could be expressed for an extended period of time. We transfected MC.GFP and MC.hAR in HEK293T cells to measure expression duration (Figure 3). The initial transfection efficiency was approximately 80% (Figure 3, Left panel). We found that GFP expression was still approximately 10% after 4 passages (around 14 days; Figure 3, right panel) of both plasmids. The data suggest that MC DNA : LPD delivery exhibits excellent capacity for long-term expression.

The ideal gene delivery system is one that can efficiently and durably express genes in target organs without chromosome insertion. We, therefore, tested whether AR-carrying minicircle DNA could be expressed in normal livers and liver tumors. We found that minicircle DNA : LPD complex could deliver DNA into normal liver (Figures 4(a), 4(c), and 4(e)) and tumor liver (Figures 4(b), 4(d), and 4(f)). In addition, the GFP signal was detected in livers two months after injection.

Taken together, minicircle DNA exerts durable expression after in vitro transfection as well as in vivo delivery using Minicircle DNA : LPD complex into normal and tumor liver for 2 months.

4. Discussion

4.1. Failure of Viral Delivery Systems

Viral-backbone modified vectors can be used as delivery systems for DNA molecules, especially plasmids [33, 34]. For therapeutic purposes, the transgene of interest is assembled in the viral genome, where the virus uses its innate mechanism of infection to enter the cells and release the expression cassette. The gene then enters the nucleus and sometimes integrates into the host genome (i.e., lentiviral vector) and is eventually expressed. Gene expression using viral vectors has been achieved with high transfection efficiencies in organs such as kidney [35], muscle [36], ovary [37], and liver [38, 39]. However, there are several concerns regarding the use of viruses as delivery vectors. The chief concern is the toxicity of the viruses and the potential for generating a strong immune response owing to their capsids. Such toxicities have been observed in numerous animal models [40, 41]. For example, traces of adenovirus titers were detected in seminal fluids of a male patient who had earlier received adenoviral based gene therapy, further compounding the fear of possible germline tampering [42]. Adenoviral vectors used for gene therapy for cystic fibrosis were shown to cause a strong immunogenic response [43]. The death of a patient with respiratory and multiple organ failure participating in a FDA-approved gene therapy clinical trial in 1999 was attributed to lethal immune response to the adenovirus vector used to deliver the gene. This case led to temporary suspension of all gene therapy trials in the United States [44]. Although clinical trials have resumed, this event as well as a few others (Clinical trial ID number: NCT00844623) and (±vector%2C±liver&Search=Search) has raised tremendous concern over the safety of using viruses for gene therapy.

In addition, the integration of therapeutic genes into the host genome by a virus takes place in a random fashion. There is no control over the exact location of the insertion of a gene. Random gene insertion can cause insertion mutagenesis that may inhibit expression of normal cellular genes or activate oncogenes, with deleterious consequences [45]. Both these two concerns are not occur while using minicircle DNA : LPD technology for nonviral mediated gene transduction nature, and not chromosome-insertion-sequence contain in minicircle DNA.

4.2. Advantages of the Minicircle-LPD Delivery System and Its Potential for Future Cancer Therapy

In contrast to viral delivery systems, lipid nanoparticles are generally less immunogenic owing to the surface PEGylation [46]. However, toxicity related to liposomal gene transfer has been observed. Acute inflammation reactions have been observed in animals treated with airway instillation and intravenous injection of lipoplex [47]. Symptoms include induction of inflammatory cytokines, neutrophil infiltration in lungs, decrease in white cell counts, and in some cases tissue injury in liver and spleen [48]. Part of the inflammatory response seen in treated lungs is related to the unmethylated CpG sequences found in plasmids of bacterial origin. A potent immune stimulant, unmethylated CpG sequences, triggers release of proinflammatory cytokines [14]. Cationic lipids in lipoplexes are capable of enhancing the unmethylated CpG effect [49]. Minicircle DNA, which is devoid of bacterial unmethylated CpG sequences, reduces immune response caused by unmethylated CpG, enhances expression level, and prolongs expression duration [16]. Further, minicircle DNA was condensed by protamine, was wrapped as a core by lipids, and therefore reduced the opportunity of exposing to immune cells to cause immune response. Another advantage of using the LPD delivery system is that LPD tends to accumulate in tumors because of the EPR effect, thus greatly enhancing selectivity [1].

5. Conclusion

To the best of our knowledge, this is the first study to use minicircle DNA-LPD to deliver a metastasis suppressor gene in normal and spontaneous-tumor livers. In this study, we used LPD containing minicircle DNA to deliver a 100 kD protein to normal and tumor livers in mice. Our results show that AR protein was robustly expressed for at least two months. The applications of this success would be in the following aspects:(1)cancer therapies usually require a long lasting concentration or expression in the target organ in order to have therapeutic effects. Our model would serve this purpose;(2)one disadvantage of viral-mediated gene therapy would be the systemic immune response caused by viral particle. The LPD carrying minicircle DNA has minimal immune problem which allows for multiple interventions.


EPR:Enhanced permeability and retention
HCC:Hepatocellular carcinoma
kbps:Kilo-base pairs
HBV:Hepatitis B Virus
AR:Androgen receptor
GFP:Green fluorescence protein
cDNA:Complementary DNA
FIX:Factor IX
ARE:Androgen response element.

Conflict of Interests

All the authors claimed no conflict of interests in this work.

Authors’ Contribution

Tian-You Chang and Chin-Ying Chung executed on majority of the experiments and draft the paper. Wei-Min Chuang is responsible for animal breeding, housing, and injections. Long-Yuan Li and Long-Bin Jeng contributed on scientific opinions and paper editing. Wen-Lung Ma designed, composed the paper, and supported the entire project. Tian-You Chang and Chin-Ying Chung contributed equally on this work.


The authors deeply appreciated Professor James Ou in University of Southern California for providing HBV-transgene mouse. This work was supported by Taiwan National Science Council Grants NSC101-2314-B-039-027-MY3 and National Health Research Institution Grants NHRI-EX102-10214BC to Wen-Lung Ma and NSC102-2321-B-039-002, NSC102-2325-B-039-002, NSC99-2632-B-039-001-MY3, and MOHW102-TD-PB-111-NSC105 to Long-Yuan Li. Tian-You Chang and Chin-Ying Chung contributed equally in this work.


  1. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,” Journal of Controlled Release, vol. 65, no. 1-2, pp. 271–284, 2000. View at: Publisher Site | Google Scholar
  2. H. Maeda, “SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy,” Advanced Drug Delivery Reviews, vol. 46, no. 1–3, pp. 169–185, 2001. View at: Publisher Site | Google Scholar
  3. P. A. Vasey, S. B. Kaye, R. Morrison et al., “Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates,” Clinical Cancer Research, vol. 5, no. 1, pp. 83–94, 1999. View at: Google Scholar
  4. F. Liu, Y. K. Song, and D. Liu, “Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA,” Gene Therapy, vol. 6, no. 7, pp. 1258–1266, 1999. View at: Publisher Site | Google Scholar
  5. X. Gao, K.-S. Kim, and D. Liu, “Nonviral gene delivery: what we know and what is next,” AAPS Journal, vol. 9, no. 1, article 9, pp. E92–E104, 2007. View at: Google Scholar
  6. C. H. Miao, A. R. Thompson, K. Loeb, and X. Ye, “Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo,” Molecular Therapy, vol. 3, no. 6, pp. 947–957, 2001. View at: Publisher Site | Google Scholar
  7. C. H. Miao, X. Ye, and A. R. Thompson, “High-level factor VIII gene expression in vivo achieved by nonviral liver-specific gene therapy vectors,” Human Gene Therapy, vol. 14, no. 14, pp. 1297–1305, 2003. View at: Publisher Site | Google Scholar
  8. J. Jiang, E. Yamato, and J.-I. Miyazaki, “Intravenous delivery of naked plasmid DNA for in vivo cytokine expression,” Biochemical and Biophysical Research Communications, vol. 289, no. 5, pp. 1088–1092, 2001. View at: Publisher Site | Google Scholar
  9. J. Yang, S. Chen, L. Huang, G. K. Michalopoulos, and Y. Liu, “Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth,” Hepatology, vol. 33, no. 4, pp. 848–859, 2001. View at: Publisher Site | Google Scholar
  10. S. F. Aliño, A. Crespo, and F. Dasí, “Long-term therapeutic levels of human alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral DNA,” Gene Therapy, vol. 10, no. 19, pp. 1672–1679, 2003. View at: Publisher Site | Google Scholar
  11. J. R. Ortaldo, R. T. Winkler-Pickett, E. W. Bere Jr., M. Watanabe, W. J. Murphy, and R. H. Wiltrout, “In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells,” Journal of Immunology, vol. 175, no. 2, pp. 693–699, 2005. View at: Google Scholar
  12. T. Suda and D. Liu, “Hydrodynamic gene delivery: its principles and applications,” Molecular Therapy, vol. 15, no. 12, pp. 2063–2069, 2007. View at: Publisher Site | Google Scholar
  13. A. M. Krieg, “Direct immunologic activities of CpG DNA and implications for gene therapy,” Journal of Gene Medicine, vol. 1, no. 1, pp. 56–63, 1999. View at: Google Scholar
  14. G. McLachlan, B. J. Stevenson, D. J. Davidson, and D. J. Porteous, “Bacterial DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to mouse lungs,” Gene Therapy, vol. 7, no. 5, pp. 384–392, 2000. View at: Google Scholar
  15. Z.-Y. Chen, C.-Y. He, A. Ehrhardt, and M. A. Kay, “Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo,” Molecular Therapy, vol. 8, no. 3, pp. 495–500, 2003. View at: Publisher Site | Google Scholar
  16. N. S. Yew, H. Zhao, M. Przybylska et al., “CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo,” Molecular Therapy, vol. 5, no. 6, pp. 731–738, 2002. View at: Publisher Site | Google Scholar
  17. P. L. Felgner, T. R. Gadek, M. Holm et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 21, pp. 7413–7417, 1987. View at: Google Scholar
  18. D. Liu, T. Ren, and X. Gao, “Cationic transfection lipids,” Current Medicinal Chemistry, vol. 10, no. 14, pp. 1307–1315, 2003. View at: Google Scholar
  19. T. Merdan, J. Kopeček, and T. Kissel, “Prospects for cationic polymers in gene and oligonucleotide therapy against cancer,” Advanced Drug Delivery Reviews, vol. 54, no. 5, pp. 715–758, 2002. View at: Publisher Site | Google Scholar
  20. X. Gao and L. Huang, “Potentiation of cationic liposome-mediated gene delivery by polycations,” Biochemistry, vol. 35, no. 3, pp. 1027–1036, 1996. View at: Publisher Site | Google Scholar
  21. S.-D. Li, S. Chono, and L. Huang, “Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles,” Journal of Controlled Release, vol. 126, no. 1, pp. 77–84, 2008. View at: Publisher Site | Google Scholar
  22. S.-D. Li, Y.-C. Chen, M. J. Hackett, and L. Huang, “Tumor-targeted delivery of siRNA by self-assembled nanoparticles,” Molecular Therapy, vol. 16, no. 1, pp. 163–169, 2008. View at: Publisher Site | Google Scholar
  23. S.-D. Li and L. Huang, “Nanoparticles evading the reticuloendothelial system: role of the supported bilayer,” Biochimica et Biophysica Acta, vol. 1788, no. 10, pp. 2259–2266, 2009. View at: Publisher Site | Google Scholar
  24. C. Chang, J. Kokontis, and S. Liao, “Molecular cloning of human and rat complementary DNA encoding androgen receptors,” Science, vol. 240, no. 4850, pp. 324–326, 1988. View at: Google Scholar
  25. C.-L. Ma, C.-L. Hsu, M.-H. Wu et al., “Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma,” Gastroenterology, vol. 135, no. 3, pp. 947–955, 2008. View at: Publisher Site | Google Scholar
  26. M.-H. Wu, W.-L. Ma, C.-L. Hsu et al., “Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription,” Science Translational Medicine, vol. 2, no. 32, article 32ra35, 2010. View at: Publisher Site | Google Scholar
  27. W. L. Ma, C. L. Hsu, C. C. Yeh et al., “Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis,” Hepatology, vol. 56, pp. 176–185, 2012. View at: Google Scholar
  28. Y. Zheng, W.-L. Chen, S. G. Louie, T. S. B. Yen, and J.-H. J. Ou, “Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice,” Hepatology, vol. 45, no. 1, pp. 16–21, 2007. View at: Publisher Site | Google Scholar
  29. M. A. Kay, C.-Y. He, and Z.-Y. Chen, “A robust system for production of minicircle DNA vectors,” Nature Biotechnology, vol. 28, no. 12, pp. 1287–1289, 2010. View at: Publisher Site | Google Scholar
  30. Y. Zheng, J. Li, and J.-H. Ou, “Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein,” Journal of Virology, vol. 78, no. 13, pp. 6908–6914, 2004. View at: Publisher Site | Google Scholar
  31. J. Li, Z. Xu, Y. Zheng, D. L. Johnson, and J.-H. Ou, “Regulation of hepatocyte nuclear factor 1 activity by wild-type and mutant hepatitis B virus X proteins,” Journal of Virology, vol. 76, no. 12, pp. 5875–5881, 2002. View at: Publisher Site | Google Scholar
  32. R. E. Kingston, C. A. Chen, and J. K. Rose, “Calcium phosphate transfection,” in Current Protocols in Molecular Biology, F. M. Ausubel, Ed., chapter 9, unit 9 1, 2003. View at: Google Scholar
  33. C. Mah, B. J. Byrne, and T. R. Flotte, “Virus-based gene delivery systems,” Clinical Pharmacokinetics, vol. 41, no. 12, pp. 901–911, 2002. View at: Google Scholar
  34. M. T. Lotze and T. A. Kost, “Viruses as gene delivery vectors: application to gene function, target validation, and assay development,” Cancer Gene Therapy, vol. 9, no. 8, pp. 692–699, 2002. View at: Publisher Site | Google Scholar
  35. Y.-H. H. Lien and L.-W. Lai, “Gene therapy for renal disorders: what are the benefits for the elderly?” Drugs and Aging, vol. 19, no. 8, pp. 553–560, 2002. View at: Google Scholar
  36. D. J. Wells, A. Ferrer, and K. E. Wells, “Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy,” Expert Reviews in Molecular Medicine, vol. 4, pp. 1–23, 2002. View at: Google Scholar
  37. J. K. Wolf and A. D. Jenkins, “Gene therapy for ovarian cancer (review),” International Journal of Oncology, vol. 21, no. 3, pp. 461–468, 2002. View at: Google Scholar
  38. B. Sangro, G. Mazzolini, M. Ruiz et al., “A phase i clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma,” Cancer Gene Therapy, vol. 17, no. 12, pp. 837–843, 2010. View at: Publisher Site | Google Scholar
  39. G. Tian, J. Liu, J. S. R. Zhou, and W. Chen, “Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial,” Anti-Cancer Drugs, vol. 20, no. 5, pp. 389–395, 2009. View at: Google Scholar
  40. M. A. Kay, J. C. Glorioso, and L. Naldini, “Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics,” Nature Medicine, vol. 7, no. 1, pp. 33–40, 2001. View at: Publisher Site | Google Scholar
  41. T. L. Timme, S. J. Hall, R. Barrios, S. L. C. Woo, E. Aguilar-Cordova, and T. C. Thompson, “Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice,” Cancer Gene Therapy, vol. 5, no. 2, pp. 74–82, 1998. View at: Google Scholar
  42. L. Tenenbaum, E. Lehtonen, and P. E. Monahan, “Evaluation of risks related to the use of adeno-associated virus-based vectors,” Current Gene Therapy, vol. 3, no. 6, pp. 545–565, 2003. View at: Google Scholar
  43. T. R. Flotte and B. L. Laube, “Gene therapy in cystic fibrosis,” Chest, vol. 120, no. 3, pp. 124S–131S, 2001. View at: Google Scholar
  44. S. E. Raper, N. Chirmule, F. S. Lee et al., “Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer,” Molecular Genetics and Metabolism, vol. 80, no. 1-2, pp. 148–158, 2003. View at: Publisher Site | Google Scholar
  45. S. D. Patil, D. G. Rhodes, and D. J. Burgess, “DNA-based therapeutics and DNA delivery systems: a comprehensive review,” The AAPS Journal, vol. 7, no. 1, article 9, pp. E61–E77, 2005. View at: Publisher Site | Google Scholar
  46. A. Vonarbourg, C. Passirani, P. Saulnier, P. Simard, J. C. Leroux, and J. P. Benoit, “Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake,” Journal of Biomedical Materials Research A, vol. 78, no. 3, pp. 620–628, 2006. View at: Publisher Site | Google Scholar
  47. Y. K. Song, “Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration,” Human Gene Therapy, vol. 8, no. 13, pp. 1585–1594, 1997. View at: Google Scholar
  48. N. S. Yew and R. K. Scheule, “Toxicity of cationic lipid-DNA complexes,” Advances in Genetics, vol. 53, pp. 189–214, 2005. View at: Publisher Site | Google Scholar
  49. N. S. Yew, K. X. Wang, M. Przybylska et al., “Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes,” Human Gene Therapy, vol. 10, no. 2, pp. 223–234, 1999. View at: Publisher Site | Google Scholar

Copyright © 2014 Tian-You Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1653 Views | 909 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.